EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Response to dabrafenib plus trametinib on a rare BRAF mutation ( V600_W604 deletion–insertion R ) in an advanced non‐small cell lung cancer patient

Akiko Tamura iD, Ryoko Inaba Higashiyama, Tatsuya Yoshida iD, Yaya Satozono, Yuichiro Ohe

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15330 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Akiko Tamura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Imidazoles, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non‐small cell lung cancer (NSCLC), data on its efficacy against uncommon BRAF mutations are still limited due to their rare frequency. We report a case of 70‐year‐old woman with BRAF V600_W604 deletion–insertion R‐positive stage IVA lung adenocarcinoma, who was successfully treated with dabrafenib plus trametinib. Herein, we discuss the oncogenic role of uncommon BRAF mutations and highlight the importance of performing comprehensive genomic profiling on patients without any targetable gene alterations in companion diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungImidazolesLung NeoplasmsOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesAgedFemaleHumansMutation

Stichwörter der Autor:innen

BRAF V600_W604 deletion–insertion RBRAF mutationcomprehensive genomic profilingdabrafenib plus trametiniblung adenocarcinoma

Substanzen

BRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinib

Autor:innen und Institutionen

  • Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Akiko Tamura, Tatsuya Yoshida

Zitieren

APA

Tamura, A., Inaba Higashiyama, R., Yoshida, T., Satozono, Y., & Ohe, Y. (2024). Response to dabrafenib plus trametinib on a rare BRAF mutation ( V600_W604 deletion–insertion R ) in an advanced non‐small cell lung cancer patient. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15330

Vancouver

Tamura A, Inaba Higashiyama R, Yoshida T, Satozono Y, Ohe Y. Response to dabrafenib plus trametinib on a rare BRAF mutation ( V600_W604 deletion–insertion R ) in an advanced non‐small cell lung cancer patient. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15330

BibTeX
@article{Tamura2024,
  author = {Tamura, Akiko and Inaba Higashiyama, Ryoko and Yoshida, Tatsuya and Satozono, Yaya and Ohe, Yuichiro},
  title = {Response to dabrafenib plus trametinib on a rare BRAF mutation ( V600_W604 deletion–insertion R ) in an advanced non‐small cell lung cancer patient},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15330}
}
Kostenlos starten →